MA59968B1 - Composés de cyclobutyle dihydroquinoléine sulfonamide - Google Patents
Composés de cyclobutyle dihydroquinoléine sulfonamideInfo
- Publication number
- MA59968B1 MA59968B1 MA59968A MA59968A MA59968B1 MA 59968 B1 MA59968 B1 MA 59968B1 MA 59968 A MA59968 A MA 59968A MA 59968 A MA59968 A MA 59968A MA 59968 B1 MA59968 B1 MA 59968B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- dihydroquinoline
- cyclobutyl
- relates
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne un composé de cyclobutyl dihydroquinoléine sulfonamide de formule (I), un énantiomère, un diastéréoisomère, un atropisomère de celui-ci, un mélange de ceux-ci, ou un sel pharmaceutiquement acceptable de celui-ci, qui inhibe des canaux sodiques voltage-dépendants, en particulier Nav1.7. Les composés sont utiles pour le traitement de maladies associées à l'activité de canaux sodiques tels que les troubles de la douleur, la toux et la démangeaison. L'invention concerne également des compositions pharmaceutiques contenant les composés de la présente invention. L'invention concerne en outre une préparation atropi-sélective desdits composés de Formule (I), et un intermédiaire de ceux-ci.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063037001P | 2020-06-10 | 2020-06-10 | |
| PCT/US2021/036896 WO2021252820A1 (fr) | 2020-06-10 | 2021-06-10 | Composés de cyclobutyle dihydroquinoléine sulfonamide |
| EP21737878.5A EP4165024B1 (fr) | 2020-06-10 | 2021-06-10 | Composés de cyclobutyle dihydroquinoléine sulfonamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA59968B1 true MA59968B1 (fr) | 2025-10-31 |
Family
ID=76797115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA59968A MA59968B1 (fr) | 2020-06-10 | 2021-06-10 | Composés de cyclobutyle dihydroquinoléine sulfonamide |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US12240839B2 (fr) |
| EP (2) | EP4653050A2 (fr) |
| JP (2) | JP7739051B2 (fr) |
| KR (1) | KR20230022996A (fr) |
| CN (2) | CN115697971B (fr) |
| AR (1) | AR122592A1 (fr) |
| AU (1) | AU2021288696A1 (fr) |
| BR (1) | BR112022025201A2 (fr) |
| CA (1) | CA3183889A1 (fr) |
| CL (1) | CL2022003499A1 (fr) |
| CO (1) | CO2022017903A2 (fr) |
| CR (1) | CR20220631A (fr) |
| DK (1) | DK4165024T3 (fr) |
| ES (1) | ES3037072T3 (fr) |
| FI (1) | FI4165024T3 (fr) |
| HR (1) | HRP20251229T1 (fr) |
| HU (1) | HUE072945T2 (fr) |
| IL (1) | IL298325A (fr) |
| JO (1) | JOP20220334A1 (fr) |
| LT (1) | LT4165024T (fr) |
| MA (1) | MA59968B1 (fr) |
| MX (2) | MX2022015856A (fr) |
| PE (1) | PE20230860A1 (fr) |
| PL (1) | PL4165024T3 (fr) |
| PT (1) | PT4165024T (fr) |
| RS (1) | RS67268B1 (fr) |
| SI (1) | SI4165024T1 (fr) |
| SM (1) | SMT202500328T1 (fr) |
| TW (1) | TWI899251B (fr) |
| UY (1) | UY39263A (fr) |
| WO (1) | WO2021252820A1 (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021195367A (ja) * | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
| JP7739051B2 (ja) | 2020-06-10 | 2025-09-16 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
| JP2024520649A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | （２ｒ，３ｓ，４ｓ，５ｒ）－４－［［３－（３，４－ジフルオロ－２－メトキシ－フェニル）－４，５－ジメチル－５－（トリフルオロメチル）テトラヒドロフラン－２－カルボニル］アミノ］ピリジン－２－カルボキサミドを含む固体剤形及び投与レジメン |
| MA64853B1 (fr) | 2021-06-04 | 2025-11-28 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hétéro)aryl) tétrahydrofuran carboxamides utilisés en tant que modulateurs de canaux sodiques |
| EP4347033A1 (fr) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | Tétrahydrofuranes à substitution hydroxy et (halo)alkoxy utiles en tant que modulateurs de canaux sodiques |
| CN117794918A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | 经取代的四氢呋喃类似物作为钠通道调节剂 |
| JP2024520648A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルの調節因子としての置換テトラヒドロフラン－２－カルボキサミド |
| CA3221939A1 (fr) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Analogues de n-(hydroxyalkyl(hetero)aryl)tetrahydrofurane carboxamide en tant que modulateurs de canaux sodiques |
| EP4385978A4 (fr) * | 2021-08-12 | 2025-08-13 | Tyk Medicines Inc | Composé polycyclique et son utilisation |
| EP4511115A1 (fr) | 2022-04-22 | 2025-02-26 | Vertex Pharmaceuticals Incorporated | Composés hétéroaryle pour le traitement de la douleur |
| JP2025513452A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| JP2025513455A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| AU2023255771A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| EP4630405A1 (fr) | 2022-12-06 | 2025-10-15 | Vertex Pharmaceuticals Incorporated | Procédé de synthèse de modulateurs de tétrahydrofurane substitués de canaux sodiques |
| WO2025090511A1 (fr) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Procédés de préparation de modulateurs de canaux sodiques et formes solides de ceux-ci pour le traitement de la douleur |
| WO2025090516A1 (fr) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Procédés de préparation de composés pour le traitement de la douleur et de formes solides de ceux-ci |
| WO2025090465A1 (fr) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Composés hétéroaryle pour le traitement de la douleur |
| WO2025090480A1 (fr) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Composés hétéroaryles pour le traitement de la douleur |
| WO2025122953A1 (fr) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Schémas posologiques et formulations de suzétrigine pour le traitement des douleurs sévères et chroniques |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2026013449A2 (fr) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Composés dérivés d'oxazolidone et leur utilisation dans le traitement de la douleur chronique et aiguë |
| WO2026030525A1 (fr) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Formes galéniques et schémas posologiques de zilvétrigine pour le traitement de la douleur |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4412994A (en) | 1980-04-24 | 1983-11-01 | Interx Research Corporation | Mannich-base hydroxamic acid prodrugs, compositions and use |
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US5707985A (en) | 1995-06-07 | 1998-01-13 | Tanabe Seiyaku Co. Ltd. | Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators |
| PA8444901A1 (es) | 1997-01-28 | 2000-05-24 | Hoffmann La Roche | Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios |
| JP4746840B2 (ja) | 2002-04-26 | 2011-08-10 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | アンドロゲン受容体モジュレーターとしての２−（キノロニル）−縮合複素環化合物 |
| MXPA05007605A (es) | 2003-01-17 | 2005-09-30 | Warner Lambert Co | Antagonista del receptor de androgenos. |
| US7009052B2 (en) | 2003-03-20 | 2006-03-07 | Warner Lambert Company Llc | Sulfonamide derivatives |
| US8076370B2 (en) | 2005-05-03 | 2011-12-13 | Ranbaxy Laboratories Limited | Antimicrobial agents |
| JP2008540539A (ja) | 2005-05-10 | 2008-11-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャンネルの調節因子としての二環系誘導体 |
| MX2007014486A (es) | 2005-05-16 | 2008-02-12 | Vertex Pharma | Derivados biciclicos como moduladores de canales ionicos. |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| TWI385161B (zh) | 2006-02-02 | 2013-02-11 | Mitsubishi Tanabe Pharma Corp | 含氮雜雙環化合物 |
| CA2741024A1 (fr) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Composes spiro-oxindole et leur utilisation comme agents therapeutiques |
| GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| CN102471235A (zh) | 2009-07-11 | 2012-05-23 | 拜耳医药股份有限公司 | 利用环烷基的放射性标记方法 |
| CN102030780B (zh) * | 2010-10-26 | 2014-01-29 | 浙江大学 | 一种手性螺环磷酸和制备方法及其应用 |
| US9079902B2 (en) | 2011-08-17 | 2015-07-14 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
| WO2013086229A1 (fr) | 2011-12-07 | 2013-06-13 | Amgen Inc. | Inhibiteurs aryle et hétéroaryle bicycliques des canaux calciques |
| WO2013122897A1 (fr) | 2012-02-13 | 2013-08-22 | Amgen Inc. | Inhibiteurs des canaux sodiques de type dihydrobenzoxazine et tétrahydroquinoxaline |
| US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| US9212182B2 (en) | 2013-06-12 | 2015-12-15 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| CN107428683B (zh) | 2015-02-04 | 2020-06-02 | 上海海雁医药科技有限公司 | 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
| JP6742331B2 (ja) | 2015-03-02 | 2020-08-19 | アムジエン・インコーポレーテツド | 二環式ケトンスルホンアミド化合物 |
| CA3008485C (fr) * | 2015-12-18 | 2023-08-01 | Amgen Inc. | Composes sulfonamides de dihydroquinoline d'alcynyle |
| NZ743377A (en) * | 2015-12-18 | 2022-05-27 | Amgen Inc | Alkyl dihydroquinoline sulfonamide compounds |
| WO2017165304A2 (fr) | 2016-03-21 | 2017-09-28 | The Scripps Research Institute | Activation énantiosélective catalysée par du pd(ii) de la liaison c(sp3)-h du bêta-méthylène |
| JP7739051B2 (ja) | 2020-06-10 | 2025-09-16 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
| JP2021195367A (ja) | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
| EP4385978A4 (fr) | 2021-08-12 | 2025-08-13 | Tyk Medicines Inc | Composé polycyclique et son utilisation |
| EP4387948A1 (fr) | 2021-08-19 | 2024-06-26 | Amgen Inc. | Préparation stéréosélective de trans-halo cyclobutane |
-
2021
- 2021-05-31 JP JP2021090960A patent/JP7739051B2/ja active Active
- 2021-06-10 CN CN202180040963.2A patent/CN115697971B/zh active Active
- 2021-06-10 IL IL298325A patent/IL298325A/en unknown
- 2021-06-10 CA CA3183889A patent/CA3183889A1/fr active Pending
- 2021-06-10 US US17/633,151 patent/US12240839B2/en active Active
- 2021-06-10 SM SM20250328T patent/SMT202500328T1/it unknown
- 2021-06-10 CN CN202510007130.6A patent/CN119735588A/zh active Pending
- 2021-06-10 MA MA59968A patent/MA59968B1/fr unknown
- 2021-06-10 UY UY0001039263A patent/UY39263A/es unknown
- 2021-06-10 KR KR1020237000972A patent/KR20230022996A/ko active Pending
- 2021-06-10 HR HRP20251229TT patent/HRP20251229T1/hr unknown
- 2021-06-10 LT LTEPPCT/US2021/036896T patent/LT4165024T/lt unknown
- 2021-06-10 WO PCT/US2021/036896 patent/WO2021252820A1/fr not_active Ceased
- 2021-06-10 FI FIEP21737878.5T patent/FI4165024T3/fi active
- 2021-06-10 TW TW110121155A patent/TWI899251B/zh active
- 2021-06-10 MX MX2022015856A patent/MX2022015856A/es unknown
- 2021-06-10 AU AU2021288696A patent/AU2021288696A1/en active Pending
- 2021-06-10 EP EP25188659.4A patent/EP4653050A2/fr active Pending
- 2021-06-10 AR ARP210101586A patent/AR122592A1/es unknown
- 2021-06-10 ES ES21737878T patent/ES3037072T3/es active Active
- 2021-06-10 JO JOP/2022/0334A patent/JOP20220334A1/ar unknown
- 2021-06-10 PL PL21737878.5T patent/PL4165024T3/pl unknown
- 2021-06-10 PT PT217378785T patent/PT4165024T/pt unknown
- 2021-06-10 BR BR112022025201A patent/BR112022025201A2/pt unknown
- 2021-06-10 EP EP21737878.5A patent/EP4165024B1/fr active Active
- 2021-06-10 DK DK21737878.5T patent/DK4165024T3/da active
- 2021-06-10 HU HUE21737878A patent/HUE072945T2/hu unknown
- 2021-06-10 PE PE2022002892A patent/PE20230860A1/es unknown
- 2021-06-10 CR CR20220631A patent/CR20220631A/es unknown
- 2021-06-10 SI SI202130354T patent/SI4165024T1/sl unknown
- 2021-06-10 RS RS20250992A patent/RS67268B1/sr unknown
- 2021-06-11 US US17/344,947 patent/US20210387978A1/en not_active Abandoned
-
2022
- 2022-12-09 MX MX2025010506A patent/MX2025010506A/es unknown
- 2022-12-09 CL CL2022003499A patent/CL2022003499A1/es unknown
- 2022-12-09 CO CONC2022/0017903A patent/CO2022017903A2/es unknown
-
2025
- 2025-01-28 US US19/039,379 patent/US20250171425A1/en active Pending
- 2025-09-02 JP JP2025145171A patent/JP2025179137A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA59968B1 (fr) | Composés de cyclobutyle dihydroquinoléine sulfonamide | |
| MX2022015622A (es) | Compuestos de dihidroquinolin sulfonamida de ciclopropilo. | |
| MA27937A1 (fr) | Dérivés d'indazole 3, 5-disubstitués, compositions pharmaceutiques, et méthodes de médiation ou d'inhibition de la prolifération cellulaire | |
| MA27647A1 (fr) | Antagonistes de ccr5 utiles comme agents therapeutiques | |
| MA27144A1 (fr) | Benzamide et heteroarylamide servant d'antagonistes du recepteur p2x7 | |
| TN2010000230A1 (fr) | Agonistes nouveaux des recepteurs de glucocorticoides | |
| MA27990A1 (fr) | Derives de piperazine pour le traitement d'infections par le vih | |
| MA31949B1 (fr) | Dérivés d'aminotriazole comme agonistes d'alx | |
| MA30073B1 (fr) | Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine | |
| MA28747B1 (fr) | Dérivés de pyridine | |
| MA31311B1 (fr) | Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p) | |
| MA33552B1 (fr) | Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques | |
| MA28746B1 (fr) | Dérivés de quinazoline-4-yl-pipéridine et cinnoline-4-yl-pipéridine servant d'inhibiteurs de PDE10 pour le traitement de troubles du SNC | |
| MA27389A1 (fr) | Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs. | |
| MA27665A1 (fr) | Triazoles substitues diaryle comme bloqueurs des canaux sodiques | |
| WO2019007696A1 (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose | |
| MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
| MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| MA26701A1 (fr) | PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT. | |
| MA27840A1 (fr) | Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2 | |
| MX2024015961A (es) | Compuesto de 3,4-dihidroquinolin-2 (1h)-ona | |
| MA70477B1 (fr) | Composés amido hétéroaromatiques utiles dans le traitement de maladies hépatiques | |
| MA27781A1 (fr) | 3-fluoro-piperidines comme antagonistes de nmda/nr2b. | |
| MX2023012039A (es) | Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos. | |
| MA29336B1 (fr) | Derives d'aryl-1,4-pyrazine substitues |